ACPTI study: Being positive in a negative situation is not naivety – Trimetazidine still has role in symptomatic CAD patients

Abstract

Results: of the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI) study showed no significant difference in the incidence of primary endpoint events between trimetazidine and placebo group in angina patients who recently underwent percutaneous coronary intervention. However, the study had limitations specific to both, design and selection of patient population. Here, we present some explanations for the null effects of trimetazidine in the ATPCI study and their relevance in routine clinical practice.

Keywords

• Percutaneous coronary intervention
• Trimetazidine
• Angina pectoris